Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|October 10, 2018
GSK, Hitachi Chemical in T-Cell Manufacturing Pact
Author(s)Pharmaceutical Technology Editors
The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.
Advertisement
GSK and Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a US subsidiary of Hitachi Chemical, announced that they have signed a three-year clinical manufacturing agreement on Oct. 1, 2018.
Under the agreement, HCATS will manufacture GSK’s specific peptide enhanced affinity receptor T-cell receptor (SPEAR) therapy for United States, Canadian and European trials. GSK’s SPEAR T-cell receptor therapy is an investigational cancer immunotherapy being
HCATS is focused on the contract manufacturing and development of cell-based cell and gene therapy products through its PCT Global Service Platform.
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement